Antengene Corporation Limited
德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ADOPTION OF THE NINTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

This announcement is made pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The board (the "**Board**") of directors (the "**Director(s)**") of Antengene Corporation Limited (the "**Company**") proposes to (a) make certain amendments (the "**Proposed Amendments**") to the existing articles of association of the Company for the purposes of, among other things, (i) providing flexibility for the Company to hold hybrid or virtual general meetings with the use of technology where members can cast votes by electronic means, (ii) better aligning the existing articles of association of the Company with the treasury shares regime under the Listing Rules, and (iii) making other consequential and housekeeping amendments; and (b) adopt the ninth amended and restated memorandum and articles of association of the Company incorporating and consolidating all the Proposed Amendments (the "**Ninth Amended and Restated Memorandum and Articles of Association**") in substitution for, and to the exclusion of, the existing memorandum and articles of association.

The Proposed Amendments as well as the adoption of the Ninth Amended and Restated Memorandum and Articles of Association are subject to approval by the shareholders of the Company at the annual general meeting to be held on Wednesday, June 10, 2026 (the "**AGM**") or any adjourned meeting by way of a special resolution and shall be effective thereupon. A circular of the Company containing, among other things, details of the Proposed Amendments as well as the adoption of the Ninth Amended and Restated Memorandum and Articles of Association together with a notice convening the AGM will be dispatched to the shareholders of the Company and published on the websites of the Stock Exchange and the Company in due course.

By order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, April 29, 2026

As at the date of this announcement, the Board comprises Dr. Jay Mei and Mr. Donald Andrew Lung as executive Directors; and Ms. Jing Qian, Mr. Sheng Tang and Dr. Rafael Fonseca as independent non-executive Directors.

About Antengene

Antengene Corporation Limited ("**Antengene**", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), and ATG-125 (B7-H3 × PD-L1 bispecific ADC).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring "2+1" bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 × CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 × CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 × CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D × CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D × CD3 (ATG-021 for multiple myeloma), LILRB4 × CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 × CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of the Directors or the Company are made as of the date of this announcement. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's annual results announcement for the year ended December 31, 2025, and the documents subsequently submitted to The Stock Exchange of Hong Kong Limited.